Lupin

Lupin, Zydus partner to co-market semaglutide injection in India

Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to therapies for diabetes and obesity

Zydus, Lupin sign deal to co-market Semaglutide injections in India

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping regulate blood sugar and appetite

Lupin eyes next US growth pillar in complex generics and biosimilars

Nearly six decades after its founding, Lupin is targeting its next global growth phase in the US with a strategy centred on complex generics, biosimilars and innovation

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Lupin rallies 12% thus far in CY26, outperforms market; here's why

In the past one month, Lupin has outperformed the market by soaring 6 per cent, as against 4.5 per cent decline in the BSE Sensex.

Further consolidation ahead for Nifty? Here's today's outlook and top picks

Ajit Mishra of Religare Broking has recommended buying the shares of Coal India, Hindustan Unilever, and Lupin today

Nifty Pharma index soars 7% thus far in February; nears 52-week high

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Stocks to Watch today, Feb 26: Lupin, IRFC, RVNL, SBI Life, Sanofi India

Stocks to Watch today, February 26, 2026: IRFC, RVNL, Sanofi India are among shares that will be eyed by investors today

Lupin gains 2%, hits 52-week high; why pharma stock in focus?

Lupin management remains confident that the India formulations business will continue to outperform IPM by 1.2-1.3 times, supported by strong sales force and pipeline of new product launches.

Stocks to Watch today, Feb 25: RIL, Schaeffler, Aditya Infotech, Hindalco

Stocks to Watch today, February 25, 2026: Schaeffler India, Aditya Infotech, RVL are among few stocks that will be in focus

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Sec sees upside in pharma, hospitals; Lupin, Aurobindo among top bets

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Stocks to Watch today, Feb 17: Cochin Shipyard, JSW Infra, Lupin, Seamec

Stocks to watch on February 17, 2026: Stocks like Cochin Shipyard, JSW Infrastructure, Lupin, TVS Supply Chain, and Seamec will remain in focus today

Stocks to buy today: Analyst at Kotak Sec bets on ICICI Bank, Lupin

Stocks to buy today: Shrikant Chouhan of Kotak Securities suggests placing bets on ICICI Bank and Lupin; here's why

Lupin rises post-Q3 analysts call, but brokerages flag FY27 earnings risk

In the December quarter, the company reported a 37 per cent growth in consolidated net profit at ₹1,175.5 crore, as compared to ₹855.16 crore a year ago

Lupin settles US patent dispute with Astellas Pharma for $90 million

The settlement resolves Lupin's ‌pending litigation with Astellas and ​enables the company to continue marketing Mirabegron in the United States

Lupin signs licensing pact with Galenicum Health for injectable Semaglutide

Drug maker Lupin on Wednesday said its subsidiary, Lupin Atlantis Holdings SA (LAHSA), has inked a licence and supply agreement with Galenicum Health for diabetes and weight management medication. Lupin Atlantis Holdings SA (LAHSA) has entered into a partnership with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. As per the agreement, Galenicum will oversee development, manufacturing, and supply, while Lupin will handle regulatory submissions, approvals, and the commercialisation and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia, and Latin America, the Mumbai-based drug maker said in a statement. "Our partnership with Galenicum marks a strategic milestone in strengthening Lupin's Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health priority, Semaglutide stands out as a critical therapy," said Fabrice Egros, President, Corporate ...

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Lupin signs exclusive India pact with Gan & Lee for fortnightly GLP-1 drug

Lupin has signed an exclusive licensing, supply and distribution deal with China's Gan & Lee for Bofanglutide, a fortnightly GLP-1 injectable for diabetes and weight management in India

US portfolio, margin expansion to drive gains for pharma major Lupin

Complex generics and better mix fuel recovery cycle